search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (36)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (15)
- General Venture Capital (46)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (67)
monthly archive
- December 2024 (1)
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Author Archives: Samantha Truex
SPAC downpour continues
July 9, 2021
By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity. In October 2020, Bruce
Ode to Scientists
April 1, 2021
By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC In the fall of 2019, I wrote a blog called Ode to Patients. As stresses from many directions have mounted over the past
Leave a Ladder Down, Part Deux
July 20, 2020
By Samantha Truex, CEO of QuenchBio, as part of the From The Trenches feature of LifeSciVC I have been privileged to read and write for this LifeSciVC blog for a handful of years now. One of my favorite editions is
Confessions Of A Planner
April 3, 2020
This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. I am a planner. I like to plan most things well in advance; in fact, maybe too far in
Ode to Patients
October 15, 2019
This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend
Tips for Industry-Academia Collaboration
July 24, 2019
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Some of the most promising and innovative research underlying biotech start-ups arises in research institutions. It
Maybe It’s Innate
April 30, 2019
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter. It’s
All A-Board
February 14, 2019
This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC. In a 2014 analysis of biotech boards and a reprise analysis in 2016, Bruce Booth
How’s My Baby?
October 24, 2018
This blog was written by Samantha Truex, CEO of Quench Bio and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. In early September, I saw my two teenagers off to new destinations where they will live
Just a Little Patience: In-licensing from Biopharma
March 20, 2018
This blog was written by Samantha Truex, an Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. People who know me well will agree that patience is not one of my personal virtues. That said, I recognize
To IPO or Not To IPO
October 25, 2017
This blog was written by Sam Truex, former CBO of Padlock and Synlogics, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC. Funding for biotech companies has been abundant this year. As covered the first
Option Or Warrant: Alternative Structures For A Future Acquisition
November 15, 2016
This blog was written by Samantha Truex, former CBO of Padlock Therapeutics and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. The search for creative deal structures that strike a “win-win” balance is a noble one.
Beyond Biotech M&A: What Comes Thereafter
September 22, 2016
This post was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. Biotech M&A is all the rage these days. Allergan has acquired four small companies in the past couple
Biotech BD Transactions: The Soft Stuff
June 27, 2016
This blog was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. I grew up in a setting where “continuous improvement” and “total quality management” were household terms, as unusual